Size:
0.09 MB
(PDF)
Rating:
Boehringer Ingelheim accesses field of oncology
Boehringer Ingelheim
Boehringer Ingelheim accesses field of oncology with three compounds in phase II – Company presents promising pipeline
Ingelheim, Germany/ Vienna, Austria, 8 November 2006
Oncology is new among Boehringer Ingelheim’s indication areas Respiratory, Cardiovascular Diseases, Virology, Central Nervous System, Immunology and Metabolic Diseases. As presented at the company’s international R&D press conference today, three anti-cancer drug candidates are now in advanced stages of development i.e. in clinical phase II.
Items: 10
Source for healthcare professionals: www.inoncology.com
* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.
© 2012 Boehringer Ingelheim GmbH. All rights reserved.
|
Terms of use
|
Imprint
Boehringer Ingelheim on
